Incidence, pathogenesis, clinical manifestations, and pharmacological management of the 2026 Andes virus outbreak
Virology Journal · 2026 · DOI: 10.1186/s12985-026-03298-9
The 2026 Andes virus outbreak highlights a severe clinical phenotype characterized by rapid-onset capillary leak, thrombocytopenia, and refractory cardiogenic shock. This observational cohort delineates the pathophysiological cascade where viral hantavirus cardiopulmonary syndrome (HCPS) triggers intense endothelial activation and myocardial depression.
Pharmacological interventions, including ribavirin, showed no mortality benefit when initiated late in the course of the disease. Early supportive care remains the cornerstone of therapy, with a high proportion of patients requiring advanced respiratory and circulatory support.